Prostaglandin-associated periorbitopathy in latanoprost users

Prostaglandin-associated periorbitopathy in latanoprost users

Shunsuke Nakakura,1 Minamai Yamamoto,1 Etsuko Terao,1 Nozomi Nagatomi,1 Naoko Matsuo,1 Yausko Fujisawa,1 Yuki Fujio,1 Hitoshi Tabuchi,1 Yoshiaki Kiuchi2 1Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan; 2Department of Ophthalmology and Visual Sciences, Graduate School of Bi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nakakura S, Yamamoto M, Terao E, Nagatomi N, Matsuo N, Fujisawa Y, Fujio Y, Tabuchi H, Kiuchi Y
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/0b319c74ffe14e3ba6c8ea869b4f5e3b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:0b319c74ffe14e3ba6c8ea869b4f5e3b
record_format dspace
spelling oai:doaj.org-article:0b319c74ffe14e3ba6c8ea869b4f5e3b2021-12-02T02:30:37ZProstaglandin-associated periorbitopathy in latanoprost users1177-5483https://doaj.org/article/0b319c74ffe14e3ba6c8ea869b4f5e3b2014-12-01T00:00:00Zhttp://www.dovepress.com/prostaglandin-associated-periorbitopathy-innbsplatanoprost-users-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Shunsuke Nakakura,1 Minamai Yamamoto,1 Etsuko Terao,1 Nozomi Nagatomi,1 Naoko Matsuo,1 Yausko Fujisawa,1 Yuki Fujio,1 Hitoshi Tabuchi,1 Yoshiaki Kiuchi2 1Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan; 2Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan Purpose: We investigated the incidence of prostaglandin-associated periorbitopathy (PAP) in subjects with glaucoma treated with latanoprost ophthalmic solution.Subjects and methods: One eye and the forehead in 22 subjects were evaluated. All patients had used latanoprost for more than 1 year (range, 12 to 45 months; mean, 26.0 months) and were prostaglandin F2α analogue treatment-naïve. Digital photographs of the subjects obtained before latanoprost therapy and at the last examination were compared retrospectively. Four signs of PAP (deepening of the upper eyelid sulcus (DUES), upper eyelid ptosis, flattening of the lower eyelid bags, and inferior scleral show) and supplemental side effects around the eyelids (eyelash growth, poliosis, and eyelid pigmentation) were judged to be negative or positive by three independent observers. If the observers unanimously rated a sign as positive, the result was defined as positive.Results: Twelve subjects (54.5%) had no apparent signs. Three subjects were judged to have DUES (13.6%), and two subjects each were judged to have flattening of the lower eyelid bags and eyelid pigmentation (9.0%). The other signs were judged as positive in only one subject each, respectively (4.5%). A univariate logistic regression analysis showed no significant associations between any of the signs and age, sex, or the duration of therapy.Conclusion: Latanoprost induced DUES, upper eyelid ptosis, flattening of the lower eyelid bags, inferior scleral show, and supplemental side effects around the eyelids; however, the rates of such occurrence might be relatively low. Keywords: glaucoma, prostaglandin F2α, deepening of the upper eyelid sulcusNakakura SYamamoto MTerao ENagatomi NMatsuo NFujisawa YFujio YTabuchi HKiuchi YDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 51-56 (2014)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Nakakura S
Yamamoto M
Terao E
Nagatomi N
Matsuo N
Fujisawa Y
Fujio Y
Tabuchi H
Kiuchi Y
Prostaglandin-associated periorbitopathy in latanoprost users
description Shunsuke Nakakura,1 Minamai Yamamoto,1 Etsuko Terao,1 Nozomi Nagatomi,1 Naoko Matsuo,1 Yausko Fujisawa,1 Yuki Fujio,1 Hitoshi Tabuchi,1 Yoshiaki Kiuchi2 1Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan; 2Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan Purpose: We investigated the incidence of prostaglandin-associated periorbitopathy (PAP) in subjects with glaucoma treated with latanoprost ophthalmic solution.Subjects and methods: One eye and the forehead in 22 subjects were evaluated. All patients had used latanoprost for more than 1 year (range, 12 to 45 months; mean, 26.0 months) and were prostaglandin F2α analogue treatment-naïve. Digital photographs of the subjects obtained before latanoprost therapy and at the last examination were compared retrospectively. Four signs of PAP (deepening of the upper eyelid sulcus (DUES), upper eyelid ptosis, flattening of the lower eyelid bags, and inferior scleral show) and supplemental side effects around the eyelids (eyelash growth, poliosis, and eyelid pigmentation) were judged to be negative or positive by three independent observers. If the observers unanimously rated a sign as positive, the result was defined as positive.Results: Twelve subjects (54.5%) had no apparent signs. Three subjects were judged to have DUES (13.6%), and two subjects each were judged to have flattening of the lower eyelid bags and eyelid pigmentation (9.0%). The other signs were judged as positive in only one subject each, respectively (4.5%). A univariate logistic regression analysis showed no significant associations between any of the signs and age, sex, or the duration of therapy.Conclusion: Latanoprost induced DUES, upper eyelid ptosis, flattening of the lower eyelid bags, inferior scleral show, and supplemental side effects around the eyelids; however, the rates of such occurrence might be relatively low. Keywords: glaucoma, prostaglandin F2α, deepening of the upper eyelid sulcus
format article
author Nakakura S
Yamamoto M
Terao E
Nagatomi N
Matsuo N
Fujisawa Y
Fujio Y
Tabuchi H
Kiuchi Y
author_facet Nakakura S
Yamamoto M
Terao E
Nagatomi N
Matsuo N
Fujisawa Y
Fujio Y
Tabuchi H
Kiuchi Y
author_sort Nakakura S
title Prostaglandin-associated periorbitopathy in latanoprost users
title_short Prostaglandin-associated periorbitopathy in latanoprost users
title_full Prostaglandin-associated periorbitopathy in latanoprost users
title_fullStr Prostaglandin-associated periorbitopathy in latanoprost users
title_full_unstemmed Prostaglandin-associated periorbitopathy in latanoprost users
title_sort prostaglandin-associated periorbitopathy in latanoprost users
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/0b319c74ffe14e3ba6c8ea869b4f5e3b
work_keys_str_mv AT nakakuras prostaglandinassociatedperiorbitopathyinnbsplatanoprostusers
AT yamamotom prostaglandinassociatedperiorbitopathyinnbsplatanoprostusers
AT teraoe prostaglandinassociatedperiorbitopathyinnbsplatanoprostusers
AT nagatomin prostaglandinassociatedperiorbitopathyinnbsplatanoprostusers
AT matsuon prostaglandinassociatedperiorbitopathyinnbsplatanoprostusers
AT fujisaway prostaglandinassociatedperiorbitopathyinnbsplatanoprostusers
AT fujioy prostaglandinassociatedperiorbitopathyinnbsplatanoprostusers
AT tabuchih prostaglandinassociatedperiorbitopathyinnbsplatanoprostusers
AT kiuchiy prostaglandinassociatedperiorbitopathyinnbsplatanoprostusers
_version_ 1718402388774092800

Ejemplares similares